159 related articles for article (PubMed ID: 35117174)
21. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.
Pal SK; Sonpavde G; Agarwal N; Vogelzang NJ; Srinivas S; Haas NB; Signoretti S; McGregor BA; Jones J; Lanman RB; Banks KC; Choueiri TK
Eur Urol; 2017 Oct; 72(4):557-564. PubMed ID: 28413127
[TBL] [Abstract][Full Text] [Related]
22. Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance.
Barata PC; Koshkin VS; Funchain P; Sohal D; Pritchard A; Klek S; Adamowicz T; Gopalakrishnan D; Garcia J; Rini B; Grivas P
Ann Oncol; 2017 Oct; 28(10):2458-2463. PubMed ID: 28945843
[TBL] [Abstract][Full Text] [Related]
23. Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung Cancer.
Fernandes MGO; Cruz-Martins N; Souto Moura C; Guimarães S; Pereira Reis J; Justino A; Pina MJ; Magalhães A; Queiroga H; Machado JC; Hespanhol V; Costa JL
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34070940
[TBL] [Abstract][Full Text] [Related]
24. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics.
Choi IS; Kato S; Fanta PT; Leichman L; Okamura R; Raymond VM; Lanman RB; Lippman SM; Kurzrock R
Mol Cancer Ther; 2019 Oct; 18(10):1852-1862. PubMed ID: 31320401
[TBL] [Abstract][Full Text] [Related]
25. The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer.
Jacob S; Davis AA; Gerratana L; Velimirovic M; Shah AN; Wehbe F; Katam N; Zhang Q; Flaum L; Siziopikou KP; Platanias LC; Gradishar WJ; Behdad A; Bardia A; Cristofanilli M
Clin Cancer Res; 2021 Mar; 27(5):1361-1370. PubMed ID: 33323406
[TBL] [Abstract][Full Text] [Related]
26. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
[TBL] [Abstract][Full Text] [Related]
27. Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies.
Shatsky R; Parker BA; Bui NQ; Helsten T; Schwab RB; Boles SG; Kurzrock R
Mol Cancer Ther; 2019 May; 18(5):1001-1011. PubMed ID: 30926636
[TBL] [Abstract][Full Text] [Related]
28. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
29. Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.
Xu S; Lou F; Wu Y; Sun DQ; Zhang JB; Chen W; Ye H; Liu JH; Wei S; Zhao MY; Wu WJ; Su XX; Shi R; Jones L; Huang XF; Chen SY; Chen J
Cancer Lett; 2016 Jan; 370(2):324-31. PubMed ID: 26582655
[TBL] [Abstract][Full Text] [Related]
30. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma.
Botrus G; Kosirorek H; Sonbol MB; Kusne Y; Uson Junior PLS; Borad MJ; Ahn DH; Kasi PM; Drusbosky LM; Dada H; Surapaneni PK; Starr J; Ritter A; McMillan J; Wylie N; Mody K; Bekaii-Saab TS
Oncologist; 2021 Jul; 26(7):569-578. PubMed ID: 33555095
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumor DNA- and cancer tissue-based next-generation sequencing reveals comparable consistency in targeted gene mutations for advanced or metastatic non-small cell lung cancer.
Huang W; Xu K; Liu Z; Wang Y; Chen Z; Gao Y; Peng R; Zhou Q
Chin Med J (Engl); 2024 May; ():. PubMed ID: 38711358
[TBL] [Abstract][Full Text] [Related]
32. Blood-based next-generation sequencing analysis of neuroendocrine neoplasms.
Zakka K; Nagy R; Drusbosky L; Akce M; Wu C; Alese OB; El-Rayes BF; Kasi PM; Mody K; Starr J; Shaib WL
Oncotarget; 2020 May; 11(19):1749-1757. PubMed ID: 32477464
[No Abstract] [Full Text] [Related]
33. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
34. The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform.
Morris LGT; Chandramohan R; West L; Zehir A; Chakravarty D; Pfister DG; Wong RJ; Lee NY; Sherman EJ; Baxi SS; Ganly I; Singh B; Shah JP; Shaha AR; Boyle JO; Patel SG; Roman BR; Barker CA; McBride SM; Chan TA; Dogan S; Hyman DM; Berger MF; Solit DB; Riaz N; Ho AL
JAMA Oncol; 2017 Feb; 3(2):244-255. PubMed ID: 27442865
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive analysis of genomic alterations detected by next-generation sequencing-based tissue and circulating tumor DNA assays in Chinese patients with non-small cell lung cancer.
Yang H; Zhang J; Zhang L; Wen X; Luo Y; Yao D; Cheng T; Cheng H; Wang H; Lou F; Guo J; Liang X; Cao S; Chen J
Oncol Lett; 2019 Nov; 18(5):4762-4770. PubMed ID: 31611986
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the Clinical Utility of Genomic Profiling to Inform Selection of Clinical Trial Therapy in Salivary Gland Cancer.
Rack S; Feeney L; Hapuarachi B; Adderley H; Woodhouse L; Betts G; Burghel GJ; Harrington KJ; Metcalf R
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267442
[TBL] [Abstract][Full Text] [Related]
37. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
[TBL] [Abstract][Full Text] [Related]
38. Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay.
Powles T; Young A; Nimeiri H; Madison RW; Fine A; Zollinger DR; Huang Y; Xu C; Gjoerup OV; Aushev VN; Wu HT; Aleshin A; Carter C; Davarpanah N; Degaonkar V; Gupta P; Mariathasan S; Schleifman E; Assaf ZJ; Oxnard G; Hegde PS
Front Oncol; 2023; 13():1221718. PubMed ID: 37601688
[TBL] [Abstract][Full Text] [Related]
39. Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival.
Kato S; Schwaederlé MC; Fanta PT; Okamura R; Leichman L; Lippman SM; Lanman RB; Raymond VM; Talasaz A; Kurzrock R
JCO Precis Oncol; 2019; 3():. PubMed ID: 31032472
[TBL] [Abstract][Full Text] [Related]
40. Identification of Genetic Alterations by Circulating Tumor DNA in Leiomyosarcoma: A Molecular Analysis of 73 Patients.
Arshad J; Barreto-Coelho P; Jonczak E; Espejo A; D'Amato G; Trent JC
J Immunother Precis Oncol; 2020 May; 3(2):64-68. PubMed ID: 36751526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
